Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vanda Pharmaceuticals Inc VNDA

Healthcare Biotechnology
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in... see more

Recent & Breaking News (NDAQ:VNDA)

Vanda Pharmaceuticals Reports Fourth Quarter 2013 and Full Year 2013 Results

PR Newswire February 13, 2014

FDA Approves HETLIOZ(TM) (tasimelteon) for the Treatment of Non-24-Hour Sleep-Wake Disorder

PR Newswire January 31, 2014

Vanda Pharmaceuticals to Announce Fourth Quarter 2013 Financial Results on February 13, 2014

PR Newswire January 23, 2014

Vanda Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference

PR Newswire December 3, 2013

TrendingWallStreet.com Shares Trend Research on GNK, SGLB, LBMH, and VNDA

Accesswire November 19, 2013

FDA Advisory Committee Recommends Approval of HETLIOZ(TM) for the Treatment of Non-24-Hour-Disorder (Non-24) in the Totally Blind

PR Newswire November 14, 2013

Vanda Pharmaceuticals Stock Trading Halted; FDA Advisory Committee to Review HETLIOZ(TM) NDA

PR Newswire November 14, 2013

SRPT, HOLX, QUIK and VNDA added to NASDAQ Active Stock Watch List at GSR

Accesswire November 12, 2013

WIN, VNDA, BIOS, GERN added to NASDAQ Active Stock Watch List at GSR

Accesswire November 7, 2013

Vanda Pharmaceuticals to Announce Third Quarter 2013 Financial Results on November 7, 2013

PR Newswire October 21, 2013

Vanda Pharmaceuticals Announces FDA Advisory Committee Meeting On November 14, 2013

PR Newswire October 16, 2013

Vanda Pharmaceuticals to Present at the Stifel Nicolaus 2013 Healthcare Conference

PR Newswire September 10, 2013

Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline -- VNDA

Globe Newswire August 23, 2013

UPCOMING DEADLINE: Levi & Korsinsky Reminds Investors With Losses in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and of August 26, 2013 Deadline to Seek a Lead Plaintiff Position -- VNDA

Globe Newswire August 21, 2013

Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline -- VNDA

Globe Newswire August 16, 2013

VANDA PHARMACEUTICALS DEADLINE ALERT: Levi & Korsinsky Notifies Investors With Losses in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 26, 2013 to Seek a Lead Plaintiff Position -- VNDA

Globe Newswire August 14, 2013

DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders of Vanda Pharmaceuticals Inc. of Upcoming Deadline

Business Wire August 12, 2013

UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 26, 2013 to Seek a Lead Plaintiff Position

Business Wire August 12, 2013

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Vanda Pharmaceuticals, Inc. to Contact the Firm -- VNDA

Globe Newswire August 9, 2013

Vanda Pharmaceuticals Inc. Prices Public Offering of Common Stock

PR Newswire August 7, 2013